OBJECTIVES:: To assess the burden of disease in peripheral Spondyloarthritis (SpA) – Psoriatic Arthritis (PsA), and axial SpA – non-radiographic axial SpA (nr-axSpA) and Ankylosing Spondylitis (AS), in Mexico and Brazil. METHODS:: Data was gathered from the Adelphi Real World 2015 DSP. Rheumatologists and dermatologists completed patient record forms (PRF) on consulting SpA patients. Patients completed questionnaires (PSC) and assessments of quality of life (SF-36, EQ-5D). RESULTS:: Health Services: Specialist-completed (n=103) PRF data on 565 patients showed that the mean number of specialist consults in the last year was 6.3 per patient, and 2.7% (n=15) of patients had been admitted to hospital to treat SpA-related complications. Approximately 4% reported having received an injection/infusion while in hospital; while 24.2% of patients reported an injection/infusion in an outpatient setting. Patient Costs: PSC cohort data (n=162) revealed that patients spent 9.2% of their quarterly household income on SpA drugs. Societal: PSC data (n=428) showed that 59% of patients were employed. Additionally, 132 patients reported a mean of 1.8 unscheduled days off in the last 3 months due to SpA. WPAI (n=215) outcomes revealed a 35.5% overall work impairment, and 425 patients reported a 39.6% activity impairment due to SpA. Humanistic: 430 respondents had an EQ-5D mean of 0.72, and the SF-36 (n=279) physical and mental component summary scores were 41.4 and 41.9 respectively. SF-36 bodily pain, social functioning, and emotional domain mean scores were 57.5, 62.9, and 63.2 respectively. Of the PSC cohort, 57% (n=157) reported that SpA has been or currently is a major problem in their life, and 74% (n=204) were concerned about possible medication side-effects. CONCLUSIONS:: This analysis shows that SpA represents a considerable burden to both patients and society overall in Mexico and Brazil. It further highlights the need for effective therapies to control both peripheral and axial Spondyloarthritis.